Background. Despite malignant glioma vascularity, anti-angiogenic therapy is largely ineffective.Wehypothesize that efficacy of the antiangiogenic agent cediranib is synergistically enhanced in intracranial glioma via combination with the late-stage autophagy inhibitor quinacrine. Methods. Relative cerebral bloodflowandvolume (rCBF, rCBV), vascular permeability (Ktrans), and tumor volume were assessed in intracranial 4C8 mouse glioma using a dual-bolus perfusionMRI approach. Tumor necrosis and tumor mean vessel density (MVD)were assessed immunohistologically. Autophagic vacuole accumulation and apoptosiswere assessed viaWestern blot in4C8glioma in vitro. Results. Cediranib or quinacrine treatment alone did not alter tumor growth. Survivalwas only marginally improved by cediranib and unchanged by quinacrine. In contrast, combined cediranib/quinacrine reduced tumor growth by >2-fold (P < .05) and increased median survival by >2- fold, compared with untreated controls (P <.05). Cediranib or quinacrine treatment alone did not significantly alter mean tumor rCBF or Ktrans compared with untreated controls, while combined cediranib/quinacrine substantially reduced both (P <.05), indicating potent tumor devascularization. MVD and necrosis were unchanged by cediranib or quinacrine treatment. In contrast, MVD was reduced by nearly 2-fold (P <.01), and necrosis increased by 3-fold (P <.05, one-tailed), in cediranib + quinacrine treated vs untreated groups.Autophagic vacuole accumulation was induced by cediranib and quinacrine in vitro. Combined cediranib/quinacrine treatment under hypoxic conditions induced further accumulation and apoptosis. Conclusion. Combined cediranib/quinacrine treatment synergistically increased antivascular/antitumor efficacy in intracranial 4C8 mouse glioma, suggesting a promising andfacile treatmentstrategy formalignant glioma.Modulations in the autophagic pathway may play a role in the increased efficacy.
|Original language||English (US)|
|Number of pages||11|
|State||Published - Dec 1 2013|
ASJC Scopus subject areas
- Clinical Neurology
- Cancer Research